Orkambi (lumacaftor/ivacaftor)

pCPA File Number: 21249

Negotiation Status:

Concluded with an LOI

Indication(s):

Cystic Fibrosis, F508del CFTR mutation

Sponsor/Manufacturer:

Vertex Pharmaceuticals (Canada) Incorporated

CDA-AMC Project Number:

Not Applicable

pCPA Engagement Letter Issued:

2020-06-12

Negotiation Process Concluded:

2021-06-03